glp 1 month results GLP-1, GLP1/GIP, and Triple G: Advanced Weight Loss Injections at LIVation Ozempic Before and After: Real

Consistency is much more effective than mega-dosing

The FDA does not verify the safety or effectiveness of compounded drugs

Some studies report a positive correlation between IGF1 and breast, colorectal, and prostate cancer

Abnormal gut microbiota in patients with T2DM and obesity promote abnormal intestinal permeability with the development of endotoxemia and systemic complications

Clinical Pearl: Ideal Candidates for Combination Therapy Patients that will greatly benefit from L-carnitine adjunctive therapy: Report persistent fatigue despite adequate weight loss on GLP-1 therapy alone Demonstrate signs of muscle loss or declining lean body mass during treatment Have plateaued in their weight loss despite medication optimization Present with metabolic syndrome features beyond elevated BMI (dyslipidemia, insulin resistance) Engage in regular physical activity and seek enhanced athletic performance alongside weight management Monitoring Parameters Regular assessment should include: Weight and body composition measurements every 4-6 weeks Lipid panel and HbA1c at 3-month intervals Liver function tests at baseline and 6 months (L-carnitine may affect hepatic fat metabolism) Patient-reported outcomes: energy levels, GI tolerability, exercise capacity Prescribing Patterns & Updates Growing Interest in Combination Metabolic Therapies Clinical practice patterns indicate increasing adoption of adjunctive therapies alongside GLP-1 medications